dashboard



Smoking weed is now more popular than smoking tobacco in the US — here are 3 simple ways to profit from the big green wave

Smoking weed is now more popular than smoking tobacco in the US — here are 3 simple ways to profit from the big green waveMarijuana stocks don’t seem to be making the big headlines they used to. But that doesn’t mean the green wave has stopped.

According to a recent Gallup poll, 16% of Americans said they smoked marijuana in the past week, while just 11% said they smoked a tobacco cigarette.

It marks the first time that smoking pot is more popular than smoking cigarettes in America. It is also the highest percentage of reported past-week marijuana use since Gallup began tracking the data since 2013.

Experimentation with the substance has also grown in America — by a lot.

In 1969, when Gallup first asked the question of whether you have ever happened to try marijuana, only 4% of Americans answered yes. Today, nearly half of Americans say they have tried it.

Let’s take a look at three marijuana stocks ready to capitalize on this trend. They are listed on stock exchanges in Canada but trade over the counter in the U.S. — analysts also see major upside in this trio.

Don’t missMitt Romney says a billionaire tax will trigger demand for these two physical assets — get in now before the super-rich swarm

You could be the landlord of Walmart, Whole Foods and Kroger (and collect fat grocery store-anchored income on a quarterly basis)

What do Ashton Kutcher and a Nobel Prize-winning economist have in common? An investing app that turns spare change into a diversified portfolio

Trulieve Cannabis Corp (TCNNF)Trulieve Cannabis entered the cannabis industry by winning the first medical marijuana application in Florida in 2015. Today, it has 100 stores in the Sunshine State, and around 150 operated and affiliated dispensaries nationwide.

The company claims that it has leading market positions not just in Florida, but also in Arizona and Pennsylvania.

Trulieve’s financials have grown tremendously, and even the COVID-19 pandemic couldn’t stop the momentum. In 2020, revenue rose 106% from the 2019 level to $521.5 million.

In 2021, revenue surged another 80% to $938.4 million.

According to the latest earnings report, Trulieve earned $320.3 million of revenue in Q2 of 2022, up 49% year over year.

The stock, however, has plunged over 40% year to date.

Canaccord analyst Derek Dley sees a rebound on the horizon. The analyst has a ‘buy’ rating on Trulieve and a price target of C$57 on its Canada-listed shares — implying a potential upside of 198%.

Green Thumb Industries (GTBIF)Green Thumb is a vertically integrated cannabis company headquartered in Chicago. It has 17 cultivation and manufacturing facilities, six consumer product brands, 77 open retail locations, and operations in 15 U.S. markets.

Just like Trulieve, Green Thumb stock hasn’t been a hot commodity: shares are down more than 30% in 2022.

Business, however, is still on the rise.

Revenue totaled $254.3 million for the quarter that ended in June, up 14.6% year over year and 4.8% sequentially.

But the best part has been the bottom line. Green Thumb earned a profit of $24.4 million for the quarter, marking its eighth consecutive quarter of positive net income.

Stifel analyst Andrew Partheniou has a ‘buy’ rating on Green Thumb and a price target of C$30.50 on its Canada-listed shares. Since these shares trade at C$17.80 right now, the price target represents a potential upside of 71%.

Curaleaf Holdings (CURLF)With a market cap of around $4.6 billion, Curaleaf is a bigger company than both Trulieve and Green Thumb.

It has a huge presence in the U.S. cannabis industry, with 26 cultivation sites, approximately 4.4 million square feet of cultivation capacity, 136 retail locations and more than 2,150 wholesale partner accounts.

During the second quarter, revenue grew 8% year over year to $338 million.

Notably, Curaleaf has a strong focus on research and development: around one-fifth of its Q2 revenue came from new products launched in the last 12 months.

Still, this pot heavyweight is not immune to the industry-wide sell-off as shares are down over 20% year to date.

Alliance Global Partners analyst Aaron Grey has a ‘buy’ rating on Curaleaf and a price target of C$12 on its Canada-listed shares — roughly 45% above where they sit today.

What to read nextSign up for our MoneyWise investing newsletter to receive a steady flow of actionable ideas from Wall Street's top firms.

Warren Buffett likes these 2 investment opportunities outside of the stock market

'Imagine you are laid off’: Suze Orman's tough-love tips to prepare for the recession ahead

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
Click Here To Get Funded!